Therapy Areas: Oncology
Innovent doses first colorectal cancer patient with IBI363/TAK-928 in combination with bevacizumab
6 August 2026 - China-based biopharmaceutical company Innovent Biologics Inc (HKEX: 01801) announced on Wednesday that the first patient has been dosed in a pivotal study evaluating IBI363 (Takeda R&a...
Citius Oncology reports growing LYMPHIR adoption and market access
5 August 2026 - Biopharmaceutical company Citius Oncology Inc (Nasdaq: CTOR), a subsidiary of Citius Pharmaceuticals Inc (Nasdaq: CTXR), on Wednesday reported continued commercial progress for LYMPHIR...
Obsidian Therapeutics advances Agni-01 study with first patient enrolled in registration-enabling cohort
5 August 2026 - Clinical-stage biopharmaceutical company Obsidian Therapeutics Inc (Nasdaq:OBX) on Wednesday announced enrolment of the first patient in the registration-enabling cohort of its Phase 1...
Summit Therapeutics expands ivonescimab programme into bladder cancer with Phase II/III trial
5 August 2026 - Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ: SMMT) reported on Wednesday that it has expanded the global clinical development programme for its investigational b...
Lilly secures FDA Breakthrough Therapy designation for olomorasib in pancreatic cancer
3 August 2026 - Medicine company Eli Lilly and Company (NYSE: LLY) announced on Monday that it has received U.S. Food and Drug Administration Breakthrough Therapy designation for olomorasib as a monot...
Genprex collaborates with Roche Diagnostics on NSCLC biomarker validation
3 August 2026 - Gene therapy company Genprex Inc (NASDAQ: GNPX) disclosed on Monday that it has entered into a collaboration with Roche Diagnostics to validate biomarkers for patient selection in non-...